Viral infectious disease
MONDO:0005108Any disease caused by a virus.
Also known as: Viruses caused disease or disorder, Viruses disease or disorder, Viruses infection, Viruses infectious disease, infection, viral, viral disease, viral disorder, viral infection
4436 clinical trials for this condition and its sub-types, 133 tagged with Viral infectious disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Viral infectious disease
-
Primary viral infectious disease 0 trials · 4,241 incl. sub-types
32 sub-types
- Viral sexually transmitted disease 5 trials · 1,589 incl. sub-types Sub-types →
- Lentivirus infection 2 trials · 1,565 incl. sub-types Sub-types →
- Nidovirales infectious disease 8 trials · 995 incl. sub-types Sub-types →
- Viral hepatitis 12 trials · 443 incl. sub-types Sub-types →
- Influenza 332 trials · 343 incl. sub-types Sub-types →
- Herpesviridae infectious disease 7 trials · 304 incl. sub-types Sub-types →
- Human papilloma virus infection 297 trials · 303 incl. sub-types Sub-types →
- Hepadnaviridae infectious disease 0 trials · 274 incl. sub-types Sub-types →
- Mononegavirales infectious disease 0 trials · 217 incl. sub-types Sub-types →
- Flaviviridae infectious disease 1 trial · 97 incl. sub-types Sub-types →
- Picornaviridae infectious disease 0 trials · 55 incl. sub-types Sub-types →
- Adenoviridae infectious disease 43 trials · 44 incl. sub-types Sub-types →
- Monkeypox 40 trials
- Bunyaviridae infectious disease 1 trial · 39 incl. sub-types Sub-types →
- Togaviridae infectious disease 0 trials · 32 incl. sub-types Sub-types →
- Deltaretrovirus infections 1 trial · 32 incl. sub-types Sub-types →
- Viral pneumonia 27 trials Sub-types →
- Viral encephalitis 3 trials · 17 incl. sub-types Sub-types →
- Smallpox 15 trials Sub-types →
- Rotavirus infection 12 trials
- Caliciviridae infectious disease 6 trials · 10 incl. sub-types Sub-types →
- Plantar wart 9 trials
- Rubella 9 trials Sub-types →
- Arenaviridae infectious disease 1 trial · 8 incl. sub-types Sub-types →
- Polyomavirus infectious disease 6 trials
- Viral exanthem 0 trials · 3 incl. sub-types Sub-types →
- Viral myocarditis 2 trials
- Cowpox 1 trial
- Astroviridae infectious disease 0 trials
- Aleutian mink disease, human 0 trials
- Phlebotomus fever 0 trials
- Viral pericarditis 0 trials
-
Viral respiratory tract infection 47 trials · 564 incl. sub-types
6 sub-types
- Influenza 332 trials · 343 incl. sub-types Sub-types →
- Respiratory syncytial virus infectious disease 168 trials · 170 incl. sub-types Sub-types →
- Common cold 36 trials
- Viral pneumonia 27 trials Sub-types →
- Hantavirus pulmonary syndrome 2 trials
- Viral laryngitis 0 trials
-
Coronavinae infectious disease 134 trials
-
Disease arising from reactivation of latent virus 4 trials · 89 incl. sub-types
3 sub-types
- Herpes zoster 73 trials Sub-types →
- Genital herpes 8 trials Sub-types →
- Herpes labialis 5 trials Sub-types →
-
Viral infection of central nervous system 3 trials · 58 incl. sub-types
7 sub-types
- Poliomyelitis 28 trials · 39 incl. sub-types Sub-types →
- Viral encephalitis 3 trials · 17 incl. sub-types Sub-types →
- Venezuelan equine encephalitis 1 trial
- Lymphocytic choriomeningitis 1 trial
- Central nervous system AIDS arteritis 0 trials
- Geniculate herpes zoster 0 trials
- Meningitis caused by poliovirus 0 trials
-
Viral hemorrhagic fever 10 trials · 51 incl. sub-types
16 sub-types
- Ebola hemorrhagic fever 21 trials
- Dengue hemorrhagic fever 7 trials Sub-types →
- Arenavirus hemorrhagic fever 0 trials · 6 incl. sub-types Sub-types →
- Crimean-Congo hemorrhagic fever 5 trials
- Marburg hemorrhagic fever 4 trials
- Rift valley fever 3 trials
- Hantavirus pulmonary syndrome 2 trials
- Venezuelan equine encephalitis 1 trial
- Hemorrhagic fever-renal syndrome 1 trial
- Bolivian hemorrhagic fever 0 trials
- Brazilian hemorrhagic fever 0 trials
- Chapare hemorrhagic fever 0 trials
- Kyasanur forest disease 0 trials Sub-types →
- Lujo hemorrhagic fever 0 trials
- Omsk hemorrhagic fever 0 trials
- Venezuelan hemorrhagic fever 0 trials
-
Arbovirus fever 0 trials · 46 incl. sub-types
2 sub-types
- Chikungunya 31 trials
- Yellow fever 16 trials
-
Kaposi's sarcoma 45 trials
4 sub-types
- Classic Kaposi sarcoma 3 trials
- Endemic Kaposi sarcoma 1 trial
- Iatrogenic Kaposi's sarcoma 1 trial
- Colorectal Kaposi sarcoma 0 trials Sub-types →
-
Human T-lymphotropic virus 1 infectious disease 5 trials · 34 incl. sub-types
2 sub-types
- Adult T-cell leukemia/lymphoma 31 trials
- Tropical spastic paraparesis 3 trials
-
Rabies 27 trials
-
Common wart 26 trials
-
Vaccinia 17 trials
-
Immunodeficiency 32B 9 trials
-
Arbovirus infection 8 trials
-
Viral eye infection 0 trials · 8 incl. sub-types
5 sub-types
- Herpes simplex virus keratitis 1 trial · 4 incl. sub-types Sub-types →
- Cytomegalovirus retinitis 2 trials
- Viral conjunctivitis 1 trial · 2 incl. sub-types Sub-types →
- Herpes zoster with dermatitis of eyelid 0 trials
- Infectious epithelial keratitis 0 trials
-
Human infection by orthopoxvirus 5 trials
-
Herpangina 3 trials
-
Milker's nodule 3 trials
-
Parvoviridae infectious disease 1 trial
2 sub-types
- Aleutian mink disease, human 0 trials
- Fetal parvovirus syndrome 0 trials
-
Zika virus congenital syndrome 1 trial
-
Molluscum contagiosum 1 trial
-
Pharyngoconjunctival fever 1 trial
-
Newcastle disease 0 trials
-
Reoviridae infectious disease 0 trials
-
Whitewater Arroyo hemorrhagic fever 0 trials
-
Congenital varicella syndrome 0 trials
-
Contagious pustular dermatitis 0 trials
-
Epidemic pleurodynia 0 trials
-
Exanthema subitum 0 trials
-
Focal epithelial hyperplasia 0 trials
-
Lumpy skin disease 0 trials
-
Neurolymphomatosis 0 trials
-
Pseudorabies 0 trials
-
Viral esophagitis 0 trials
-
Viral gastritis 0 trials
1 sub-type
- Herpetic gastritis 0 trials
-
Viral labyrinthitis 0 trials
-
Viral myositis 0 trials
Most studied deeper sub-types
-
Can a Self-Amplifying mRNA vaccine outsmart COVID-19?
Vaccine CompletedThis first-in-human trial is testing an experimental vaccine that uses self-amplifying mRNA technology to target the SARS-CoV-2 spike protein. The study involves healthy adults aged 18 to 50 who receive two doses a month apart. The main goals are to assess the vaccine's safety, s…
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Aug 26, 2026 00:00 UTC
-
Can an mRNA vaccine shield the most vulnerable from RSV?
Vaccine CompletedThis phase 3 trial is testing an experimental mRNA vaccine called mRNA-1345 to see if it can protect against respiratory syncytial virus (RSV) in adults who are at high risk of severe illness. The study includes two groups: adults aged 18 to 59 with chronic health conditions like…
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 22, 2026 00:00 UTC
-
Can an mRNA vaccine shield vulnerable children from RSV?
Vaccine CompletedThis phase 2 trial evaluates an experimental mRNA vaccine (mRNA-1345) designed to protect against respiratory syncytial virus (RSV) in children aged 2 to under 18 who are at high risk of severe RSV disease. The study will assess the vaccine's safety, side effects, and immune resp…
Phase 2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 20, 2026 00:00 UTC
-
New COVID shot tested in vulnerable kids
Vaccine CompletedThis Phase 3 trial tests an updated COVID-19 vaccine (BNT162b2, 2025/2026 formulation) in 343 children aged 5 to 11 who have medical conditions that put them at high risk for severe COVID-19. All participants receive one dose and are monitored for about 6 months to check safety a…
Phase 3 • Sponsor: BioNTech SE • Aim: Vaccine
Last updated Aug 09, 2026 00:00 UTC
-
New experimental flu vaccine aims to outsmart the flu virus
Vaccine CompletedThis early-stage study tested an experimental flu vaccine called FluMos-v2 in 30 healthy adults aged 18 to 50. The vaccine is designed to protect against multiple flu strains at once, unlike current vaccines that target only one. Participants received two shots four months apart …
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Jul 15, 2026 00:00 UTC
-
New COVID vaccine trial aims to outsmart evolving variants
Vaccine CompletedThis study tests an updated COVID-19 vaccine (mRNA-1283) designed to protect against current virus variants. About 832 people aged 12 and older, especially those at higher risk, will receive the vaccine. Researchers will measure immune response and monitor for side effects to ens…
Phase 4 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jul 09, 2026 00:00 UTC
-
Could a shot during pregnancy shield babies from RSV?
Vaccine CompletedThis study tested an mRNA vaccine (mRNA-1345) against respiratory syncytial virus (RSV) in 360 pregnant women. The goal was to see if the vaccine is safe for mothers and their babies, and whether it triggers an immune response that could protect infants after birth. Participants …
Phase 2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 13:07 UTC
-
New mRNA flu shots show promise in large adult trial
Vaccine CompletedThis study tested new mRNA-based seasonal flu vaccines in 776 healthy adults aged 18 and older. The goal was to see how safe the vaccines are and how well they boost the immune system. Researchers measured side effects and immune responses to find the best vaccine candidate.
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jun 27, 2026 12:38 UTC
-
New bird flu booster shot shows promise in early trial
Vaccine CompletedThis study tested a booster vaccine for H5N6 bird flu in about 260 adults. Some had previously received an H5N1 bird flu vaccine, while others had not. The goal was to see if the booster was safe and triggered a strong immune response. Participants received one or two doses of th…
Phase 2 • Sponsor: Seqirus • Aim: Vaccine
Last updated Jun 27, 2026 12:33 UTC
-
New mRNA vaccine shows promise against common virus that can harm newborns
Vaccine CompletedThis study tested an experimental mRNA vaccine called mRNA-1647 to see if it is safe and triggers an immune response against cytomegalovirus (CMV). The trial involved 315 healthy adults aged 18 to 40, some of whom had never been exposed to CMV. Researchers measured side effects a…
Phase 2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC
-
New mRNA shingles shot shows promise in early trial
Vaccine CompletedThis early-stage study tested a new mRNA vaccine called IN001 for preventing shingles in 150 healthy adults aged 50 to 69. The main goals were to check the vaccine's safety, side effects, and how well it triggers the immune system. Researchers gave different doses to find the bes…
Phase 1 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: Vaccine
Last updated Jun 27, 2026 12:02 UTC
-
Moderna's mRNA vaccine cocktail passes early safety check
Vaccine CompletedThis study tested the safety and immune response of several Moderna mRNA vaccines for COVID-19, seasonal flu, RSV, and CMV in 308 healthy adults aged 18 to 75. Researchers monitored side effects and measured antibody levels after vaccination. The goal was to ensure the vaccines a…
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 11:00 UTC
-
Moderna's CMV vaccine shows promise in Long-Term Follow-Up study
Vaccine CompletedThis study is a long-term follow-up of a phase 2 trial testing Moderna's mRNA-1647 vaccine against cytomegalovirus (CMV). It involves 135 adults who previously received the vaccine or a placebo. Researchers are checking how long the immune response lasts and whether a booster dos…
Phase 2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 09:01 UTC
-
New mRNA RSV vaccine shows promise for older adults in phase 3 trial
Vaccine CompletedThis phase 3 study tested an mRNA vaccine called mRNA-1345 to protect against respiratory syncytial virus (RSV) in adults aged 50 and older. Over 3,300 participants received the vaccine alone, with a flu shot, or with a COVID-19 booster. The trial also looked at a booster dose on…
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 08:07 UTC
-
One shot for two viruses? moderna tests combo mRNA vaccine
Vaccine CompletedThis early-stage trial tested several experimental mRNA vaccines that aim to protect against both influenza and SARS-CoV-2 in a single injection. About 1,758 healthy adults aged 18 to under 80 took part. The main goals were to check safety and measure the immune response, with re…
Phase 1/2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 08:06 UTC
-
New COVID booster vaccine shows promise in early trial
Vaccine CompletedThis study tested a new COVID-19 booster vaccine called SpiN-Tec in 432 healthy adults aged 18 to 85 who had already received full vaccination and at least one booster. The vaccine was compared to approved boosters like Covishield and Comirnaty. The goal was to check safety and w…
Phase 1/2 • Sponsor: Federal University of Minas Gerais • Aim: Vaccine
Last updated Jun 26, 2026 17:23 UTC
-
Moderna vaccine shows promise for teens in large trial
Vaccine CompletedThis completed Moderna trial tested the mRNA-1273 COVID-19 vaccine in over 4,300 healthy adolescents aged 12 to 17. The study looked at safety, side effects, and how well the vaccine works to prevent COVID-19. Participants received either the vaccine or a placebo, and some later …
Phase 2/3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 26, 2026 17:09 UTC
-
Boosting the immune system after transplant: could 'Killer' cells prevent relapse?
Disease control CompletedThis study tests whether giving patients their own specially grown immune cells (called cytokine-induced killer cells) shortly after a stem cell transplant is safe. The trial enrolls adults with lymphoma who are receiving a transplant of their own stem cells. Researchers will mon…
Sponsor: LucasBio • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Personalized immune cell therapy aims to clear stubborn COVID-19 infections
Disease control CompletedThis study tests a treatment called LB-DTK-COV19, made from a patient's own immune cells, for people who have had COVID-19 symptoms or a positive test for more than 21 days. Participants receive two infusions of their personalized T cells, two weeks apart, and are followed for si…
Sponsor: LucasBio • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Cancer-Fighting virus shows promise in Hard-to-Treat ovarian cancer
Disease control CompletedThis study tested a new immunotherapy called Olvi-Vec, which uses a modified virus to attack cancer cells, in 46 patients with ovarian cancer that had come back or stopped responding to standard treatments. The goal was to see if the treatment was safe and could slow tumor growth…
Phase 1/2 • Sponsor: Genelux Corporation • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Plasma from COVID-19 survivors tested as treatment for the critically ill
Disease control CompletedThis study looked at whether giving plasma (the liquid part of blood) from people who recovered from COVID-19 could help critically ill patients fight the virus. The plan was to collect plasma from up to 240 recovered donors and give it to sick patients. However, the plasma donat…
Phase 3 • Sponsor: West Virginia University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
RSV booster shot shows promise for seniors
Disease control CompletedThis study tested a new mRNA booster shot (mRNA-1345) in 507 adults aged 60 and older who had already received a licensed RSV vaccine at least a year earlier. The goal was to see if the booster is safe and boosts the immune system's ability to fight RSV. Researchers measured side…
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New antiviral pill could shorten your next cold
Disease control CompletedThis study tested whether the antiviral drug Amizon (enisamium iodide) can help adults with colds or flu feel better faster. One hundred adults aged 18 to 60 took either Amizon or a placebo pill for 7 days, starting within a day of their first symptoms. Researchers tracked sympto…
Phase 2/3 • Sponsor: Joint Stock Company "Farmak" • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Could a common compound help fight COVID-19 and flu? small study explores
Disease control CompletedThis small pilot study tested whether a sustained-release ammonium chloride formula (with vitamin D) can reduce virus levels in adults with mild or moderate COVID-19 or influenza. 32 participants took either the active formula or a vitamin D-only control twice daily for 10 days. …
Sponsor: National and Kapodistrian University of Athens • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for COVID-19 patients on ventilators: drug combo trial completed
Disease control CompletedThis study tested two drugs—remdesivir and aviptadil—in hospitalized COVID-19 patients with severe breathing failure. About 473 participants received either a study drug plus standard care or a placebo plus standard care. The goal was to see if these drugs could safely improve ou…
Phase 3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Remdesivir put to the test in COVID-19 patients on oxygen
Disease control CompletedThis completed Phase 3 trial tested the safety and effectiveness of remdesivir in 87 hospitalized COVID-19 patients with acute respiratory distress syndrome (severe breathing failure). Participants received either remdesivir plus standard care or a placebo plus standard care for …
Phase 3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug aviptadil tested in COVID-19 lung crisis
Disease control CompletedThis phase 3 trial tested whether the drug aviptadil can help hospitalized COVID-19 patients with acute respiratory distress syndrome (ARDS). 471 participants received either aviptadil plus standard care or a placebo plus standard care. The main goal was to see how well patients …
Phase 3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could a cold virus drug prevent COPD Flare-Ups?
Disease control CompletedThis study tested whether the drug vapendavir can reduce breathing problems in people with COPD who catch a rhinovirus (common cold). Fifty-two adults with COPD were given either vapendavir or a placebo after being exposed to the virus. The main goal was to see if vapendavir lowe…
Phase 2 • Sponsor: Altesa Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Could a common antiviral protect babies from CMV in the womb?
Disease control CompletedThis study tested whether giving the antiviral drug valacyclovir to pregnant women with a CMV-infected fetus could reduce the chance of the baby being born with serious symptoms. 41 pregnant women took high doses of valacyclovir daily for up to 23 weeks. The goal was to see if th…
Phase 4 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 26, 2026 14:09 UTC
-
A simple blood test may spot severe bacterial infections faster in the ER
Diagnosis CompletedResearchers in Basel are testing whether a blood marker called HNL can help emergency doctors quickly tell whether an infection is bacterial or viral. The study will enroll about 516 adults with suspected infection and signs of physiological disturbance. Doctors will measure HNL …
Sponsor: University Hospital, Basel, Switzerland • Aim: Diagnosis
Last updated Sep 12, 2026 00:00 UTC
-
One-Hour brain infection test could save lives
Diagnosis CompletedThis study tested a new rapid diagnostic panel called QIAstat-Dx that can detect 15 different bacteria, viruses, and fungi causing meningitis and encephalitis in just one hour. Researchers compared its accuracy against standard lab tests using 170 stored spinal fluid samples. If …
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
New blood test could spot dangerous infections in feverish kids faster
Diagnosis CompletedThis study looked at whether a combination of 7 biomarkers in the blood can more accurately diagnose severe bacterial infections in children aged 7 days to 36 months with fever. Researchers enrolled 983 children and compared the biomarker panel's performance against standard test…
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
New biosensors aim to diagnose infections in minutes
Diagnosis CompletedThis study tested two new types of biosensor platforms to detect viruses, bacteria, and parasites in blood and respiratory samples. The goal was to see if these devices could be accurate, fast, and cheap alternatives to standard lab tests. Researchers enrolled 149 adults with or …
Sponsor: University of Bologna • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
New AI-Guided blood test could slash unnecessary antibiotic use
Diagnosis CompletedThis study tested a blood test that measures three proteins (ICAM1, CFHR5, and GRN) to help doctors quickly tell whether a fever is caused by bacteria or a virus. Researchers studied 394 adults with high fever and short illness duration. The goal is to improve diagnosis and reduc…
Sponsor: Qilu Hospital of Shandong University • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
New mRNA flu shots enter human testing – could they beat the old ones?
Prevention CompletedThis study tests several new mRNA-based flu vaccines in about 971 healthy adults aged 18 and older. The goal is to see how well they trigger an immune response and how safe they are compared to standard flu shots. Participants receive one dose of an experimental vaccine or a comp…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Moderna's Next-Gen COVID shot put to the test in 13,000+ people
Prevention CompletedThis large Phase 3 trial compared a new experimental mRNA COVID-19 vaccine (mRNA-1283) with Moderna's original vaccine (mRNA-1273) in over 13,500 people aged 12 and older. The goal was to see if the new vaccine is safer, triggers a better immune response, and prevents COVID-19 at…
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Prevention
Last updated Jun 27, 2026 12:28 UTC
-
Could a special light keep nursing home residents safer from flu and COVID?
Prevention CompletedThis study tested whether far-UVC light, a safe type of ultraviolet light, can reduce respiratory infections like flu and COVID-19 in long-term care facilities. The trial involved 550 elderly residents who are at higher risk due to age and health conditions. The light was used as…
Sponsor: Kenneth Rockwood • Aim: Prevention
Last updated Jun 27, 2026 08:10 UTC
-
Nerve block may fix COVID smell problems, study says
Symptom relief CompletedThis study tested whether a stellate ganglion block (an injection near nerves in the neck) can improve distorted sense of smell (parosmia) caused by COVID-19. 48 adults with long-term smell issues after COVID took part. Half received the nerve block, half got a placebo (saline). …
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
Scientists dig into mysterious kidney scarring
Knowledge-focused CompletedThis completed study looked at why some people develop scarring in their kidneys, including rare diseases like FSGS and a mysterious form of chronic kidney disease affecting farm workers. Researchers collected blood, urine, and kidney tissue from 537 participants to better unders…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Blood safety watch: 1,771 transfusion patients tracked for hidden infections
Knowledge-focused CompletedThis study followed 1,771 adults and children who received blood transfusions to check how safe the blood supply is. Researchers tested patients' blood for viruses like HIV and hepatitis before and after transfusion, and stored samples for future testing. The goal was to keep blo…
Sponsor: National Institutes of Health Clinical Center (CC) • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
730 transplant Patients' records reveal hidden viral risks
Knowledge-focused CompletedThis study reviewed medical records of 730 people who had bone marrow transplants between 2010 and 2015. Researchers wanted to learn how often viral infections happen after transplant and what factors make them more likely. No new treatments were tested; instead, the goal was to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 20, 2026 00:00 UTC
-
French hospital staff antibody study reveals infection patterns
Knowledge-focused CompletedThis study tested over 1,500 hospital workers in four French hospitals for COVID-19 antibodies to see how many had been infected. Researchers compared infection rates among staff in COVID-19 units, other care areas, and non-care roles, and across regions with different outbreak i…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Hidden danger: flu patients in ICU face fungal lung threat
Knowledge-focused CompletedThis study tracked 241 ICU patients with severe influenza to see how many developed a fungal lung infection called IAPA. Researchers collected blood and fluid samples to identify risk factors. The goal is to help doctors spot high-risk patients earlier.
Sponsor: Radboud University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Heart scan may forecast ICU stay for babies with severe bronchiolitis
Knowledge-focused CompletedThis study looked at 46 infants under 2 years old in the pediatric ICU with severe bronchiolitis. Researchers used a heart ultrasound measure called TAPSE to see if it could predict how long babies needed intensive care. The goal was to find a simple test that helps doctors plan …
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Heart transplant warning: could a simple virus test spot rejection early?
Knowledge-focused CompletedThis study followed 60 heart transplant patients for one year to see if levels of a harmless virus called TTV in the blood are linked to infections or organ rejection. Researchers took monthly blood samples alongside routine care. The goal is to find a new way to monitor transpla…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Farm life could shield children from bad colds and asthma
Knowledge-focused CompletedThis study looked at whether children who grow up on farms, with more exposure to microbes, have fewer severe colds and breathing problems. Researchers tracked 290 children aged 4 to 12, including farm kids and city kids with and without asthma. The goal was to understand how ear…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Could a mother's virus raise her baby's heart defect risk? new study investigates.
Knowledge-focused CompletedThis study looked at whether viral infections and diabetes in pregnant women are linked to congenital heart defects in their babies. Researchers analyzed blood and stool samples from 114 women to detect viruses and immune responses. The goal was to gather knowledge for future lar…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Can a simple blood test predict which COVID patients will get worse?
Knowledge-focused CompletedThis completed study from France enrolled 373 people who came to the emergency room with suspected COVID-19. Researchers checked routine blood markers to see if any could predict which patients would later get worse and need intensive care. The goal was to find simple, low-risk t…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Scientists map out antiviral Drug's journey in tiny human trial
Knowledge-focused CompletedThis completed Phase 1 study gave a single IV dose of the antiviral PF-07304814 to 5 healthy adults. Researchers measured how much of the drug ended up in urine and feces, and how it was processed in the blood. The goal was simply to understand the drug's breakdown and eliminatio…
Phase 1 • Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
How long does COVID immunity last? new study follows patients for a year
Knowledge-focused CompletedThis completed study looked at 189 adults who had COVID-19 to see how long their immune system remembers the virus. Researchers collected blood, saliva, and nose swabs at 6 and 12 months after infection to measure antibody levels. The goal was to understand if protective immunity…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:51 UTC
-
Hospital COVID spread under the microscope: 2,000+ patients and staff tracked
Knowledge-focused CompletedThis completed study looked at how the SARS-CoV-2 virus spreads within hospitals, involving over 2,000 patients, caregivers, and healthcare workers. Researchers tracked suspected and confirmed cases to identify risk factors and the effectiveness of infection control measures. The…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:00 UTC